Sign in
TerminatedPhase 2

A Study of Belcesiran in Patients With AATLD

Key facts

Who runs it
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Where
Charleston, Gainesville, and La Jolla, United StatesSee the 3 sitesAlso in 13 other countries, 20 sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
16 people enrolled
Started
12 Feb 2021
Ended
29 May 2024
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Belcesiran
  • Placebo
Record updated
7 April 2026
Why it stopped
Development project was discontinued

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • 18 to 75 years, inclusive, at the time of consent
  • Documented diagnosis of PiZZ-type alpha-1 antitrypsin deficiency, confirmed by genotyping. Historical genotyping data may be used, if available
  • AATD-associated liver disease documented by liver biopsy at Screening
  • Consent to undergo paired liver biopsies
  • Lung, renal and liver function within acceptable limits
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol

Who cannot take part

  • History of one single severe exacerbation of underlying lung disease in the year prior to randomization
  • History of clinically significant respiratory infections (including pneumonia and lower respiratory tract infections), as determined by the Investigator, in the 3 months prior to screening
  • Use of an RNAi drug at any time
  • History of chronic liver disease other than non-alcoholic fatty liver disease from any cause other than PiZZ-type alpha-1 antitrypsin deficiency
  • Child-Pugh Score B or C

Where in United States

Also in 13 other countries, 20 sites

  • Medical University of South CarolinaCharleston, United States
  • University of FloridaGainesville, United States
  • University of California San DiegoLa Jolla, United States

About the trial

What the trial wants to find out

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).

Read full original descriptionShow less

The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.

The 6 groups in the trial

  • Belcesiran Cohort 1Treatment being tested

    Treatment: Belcesiran

  • Placebo Cohort 1Placebo, for comparison

    Treatment: Placebo

  • Belcesiran Cohort 2Treatment being tested

    Treatment: Belcesiran

  • Placebo Cohort 2Placebo, for comparison

    Treatment: Placebo

  • Belcesiran Cohort 3Treatment being tested

    Treatment: Belcesiran

  • Placebo Cohort 3Placebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Record updated
7 April 2026